Role of topoisomerase mutations and efflux in fluoroquinolone resistance of Bacteroides fragilis clinical isolates and laboratory mutants

被引：31

作者：

Ricci, V

Peterson, ML

Rotschafer, JC

Wexler, H

Piddock, LJV ^{[1
]}

机构：

[1] Univ Birmingham, Div Immun & Infect, Antimicrobial Agents Res Grp, Birmingham B15 2TT, W Midlands, England

[2] Univ Minnesota, Minneapolis, MN 55455 USA

[3] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2004年 / 48卷 / 04期

关键词：

D O I：

10.1128/AAC.48.4.1344-1346.2004

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Twelve laboratory mutants and 32 ciprofloxacin-resistant isolates of Bacteroides fragilis were examined for the mechanism(s) of fluoroquinolone resistance. Five mutants had mutations in gyrA. One mutant and two clinical isolates contained a mutation in gyrB. Eight mutants and five clinical isolates accumulated significantly less ciprofloxacin than did wild-type isolates; the mutants and clinical isolates were restored to wild-type characteristics when carbonyl cyanide m-chlorophenylhydrazone was used.

引用

页码：1344 / 1346

页数：3

共 50 条

[1] Roles of gyrA mutations in resistance of clinical isolates and in vitro mutants of Bacteroides fragilis to the new fluoroquinolone trovafloxacin
Bachoual, R
Dubreuil, L
Soussy, CJ
Tankovic, J
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (07) : 1842 - 1845
[2] Role of DNA gyrase and topoisomerase IV mutations in fluoroquinolone resistance of Capnocytophaga spp. clinical isolates and laboratory mutants
Ehrmann, Elodie
Jolivet-Gougeon, Anne
Bonnaure-Mallet, Martine
Fosse, Thierry
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (08) : 2208 - 2212
[3] Efflux-mediated fluoroquinolone resistance in the Bacteroides fragilis group
Oh, H
Hedberg, M
Edlund, C
ANAEROBE, 2002, 8 (05) : 277 - 282
[4] Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae:: Contributions of type II topoisomerase mutations and efflux to levels of resistance
Bast, DJ
Low, DE
Duncan, CL
Kilburn, L
Mandell, LA
Davidson, RJ
de Azavedo, JCS
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (11) : 3049 - 3054
[5] Role of topoisomerase mutations, plasmid mediated resistance (qnr) and acrAB efflux pump in fluoroquinolone resistant clinical isolates of avian Escherichia coli
Yaqoob, M.
Wang, L. P.
Memon, J.
Kashif, J.
Umar, S.
Naseer, Z.
Iqbal, M. F.
Fiaz, M.
Lu, C. P.
MOLECULAR GENETICS MICROBIOLOGY AND VIROLOGY, 2017, 32 (01) : 49 - 54
[6] Role of topoisomerase mutations, plasmid mediated resistance (qnr) and acrAB efflux pump in fluoroquinolone resistant clinical isolates of avian Escherichia coli
M. Yaqoob
L. P. Wang
J. Memon
J. Kashif
S. Umar
Z. Naseer
M. F. Iqbal
M. Fiaz
C. P. Lu
Molecular Genetics, Microbiology and Virology, 2017, 32 : 49 - 54
[7] The role of efflux pumps in Bacteroides fragilis resistance to antibiotics
Ghotaslou, Reza
Yekani, Mina
Memar, Mohammad Yousef
MICROBIOLOGICAL RESEARCH, 2018, 210 : 1 - 5
[8] Topoisomerase mutations and efflux are associated with fluoroquinolone resistance in Enterococcus faecalis
Oyamada, Yoshihiro
Ito, Hideaki
Inoue, Matsuhisa
Yamagishi, Jun-ichi
JOURNAL OF MEDICAL MICROBIOLOGY, 2006, 55 (10) : 1395 - 1401
[9] Role of type II topoisomerase mutations and AcrAB efflux pump in fluoroquinolone-resistant clinical isolates of Proteus mirabilis
Saito, Ryoichi
Sato, Kenya
Kumita, Wakako
Inami, Natsuko
Nishiyama, Hiroyuki
Okamura, Noboru
Moriya, Kyoji
Koike, Kazuhiko
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (03) : 673 - 677
[10] Role of efflux pumps and topoisomerase mutations in fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli
Ge, BL
McDermott, PF
White, DG
Meng, JH
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (08) : 3347 - 3354

← 1 2 3 4 5 →